Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helen Hockings

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Therapeutic Advances in Medical Oncology|May 22, 2023
The role of PARP inhibitor combination therapy in ovarian cancerHelen Hockings, Rowan E Miller
Psychiatria Danubina|October 1, 2009
Is oestrogen neuroprotective?Mark Agius, Helen Hockings, Charlotte Wilson, et al.
Oncogene|February 2, 2021
The role of MET in chemotherapy resistanceGeorgina E Wood, Helen Hockings, Danielle M Hilton, et al.
Iscience|August 17, 2021
LiquidCNA: Tracking subclonal evolution from longitudinal liquid biopsies using somatic copy number alterationsEszter Lakatos, Helen Hockings, Maximilian Mossner, et al.
Cancer Research|April 29, 2025
Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor ControlHelen Hockings, Eszter Lakatos, Weini Huang, et al.
Biorxiv : the Preprint Server for Biology|August 7, 2023
Adaptive therapy achieves long-term control of chemotherapy resistance in high grade ovarian cancerHelen Hockings, Eszter Lakatos, Weini Huang, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|July 2, 2021
Learning from Crisis: a Multicentre Study of Oncology Telemedicine Clinics Introduced During COVID-19Michael Grant, Helen Hockings, Maria Lapuente, et al.
BMJ Open|January 14, 2025
Study protocol for Adaptive ChemoTherapy for Ovarian cancer (ACTOv): a multicentre phase II randomised controlled trial to evaluate the efficacy of adaptive therapy (AT) with carboplatin, based on changes in CA125, in patients with relapsed platinum-sensitive high-grade serous or high-grade endometrioid ovarian cancerUma Anne Mukherjee, Helen Hockings, Nicholas Counsell, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Therapeutic Advances in Medical Oncology|May 22, 2023
The role of PARP inhibitor combination therapy in ovarian cancerHelen Hockings, Rowan E Miller
Psychiatria Danubina|October 1, 2009
Is oestrogen neuroprotective?Mark Agius, Helen Hockings, Charlotte Wilson, et al.
Oncogene|February 2, 2021
The role of MET in chemotherapy resistanceGeorgina E Wood, Helen Hockings, Danielle M Hilton, et al.
Iscience|August 17, 2021
LiquidCNA: Tracking subclonal evolution from longitudinal liquid biopsies using somatic copy number alterationsEszter Lakatos, Helen Hockings, Maximilian Mossner, et al.
Cancer Research|April 29, 2025
Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor ControlHelen Hockings, Eszter Lakatos, Weini Huang, et al.
Biorxiv : the Preprint Server for Biology|August 7, 2023
Adaptive therapy achieves long-term control of chemotherapy resistance in high grade ovarian cancerHelen Hockings, Eszter Lakatos, Weini Huang, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|July 2, 2021
Learning from Crisis: a Multicentre Study of Oncology Telemedicine Clinics Introduced During COVID-19Michael Grant, Helen Hockings, Maria Lapuente, et al.
BMJ Open|January 14, 2025
Study protocol for Adaptive ChemoTherapy for Ovarian cancer (ACTOv): a multicentre phase II randomised controlled trial to evaluate the efficacy of adaptive therapy (AT) with carboplatin, based on changes in CA125, in patients with relapsed platinum-sensitive high-grade serous or high-grade endometrioid ovarian cancerUma Anne Mukherjee, Helen Hockings, Nicholas Counsell, et al.
Pageof 1